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LESSONS LEARNED
• Difficulties in translating in vitro results into clinical practice are inevitable.
• Further efforts to verify the efficacy of alternative schedules of pemetrexed in solid tumors are encouraged.
ABSTRACT
Background. We investigated the cytotoxic activity of peme-
trexed in combination with several drugs (gemcitabine, carbo-
platin, vinorelbine, and mitomycin C) using different exposure
schedules in three colon cancer cell lines. The best results were
obtained with the following schedule: a prolonged pemetrexed
exposure followed by a 48-hour wash-out and then gemcitabine.
This combination was then advanced to a phase II clinical trial.
Methods. Patients with metastatic colorectal cancer in progres-
sion after standard treatment were included in the study.
Adequate bonemarrow reserve, normal hepatic and renal func-
tion, and an Eastern Cooperative Oncology Group (ECOG) per-
formance status of 0–2 were required. Treatment consisted of
an 8-hour intravenous infusion of pemetrexed 150 mg/m2 on
day 1 and a 30-minute intravenous infusion of gemcitabine
1,000mg/m2 on day 3 of each cycle, repeated every 14 days.
Results. Fourteen patients were enrolled onto the study (first
step). No objective responses were seen, and evidence of stable
disease was observed in only one of the 12 evaluable patients.
The most important grade 3–4 side effects were hematological
toxicity (neutropenia 64.2%, thrombocytopenia 71.4%, anemia
28.7%), fatigue (50.0%), and stomatitis (21.5%). Median overall
survival and time to progression were 5.8 months (95% confi-
dence interval [CI]: 3.9–7.1) and 2.1 months (95% CI: 1.7–2.8),
respectively.
Conclusion. The experimental pemetrexed-gemcitabine combi-
nation proved to be inactive and moderately toxic. The
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DISCUSSION
Although gemcitabine and pemetrexed have shown preclinical
and clinical activity in patients with metastatic colorectal can-
cer, clinical data remain inconclusive [1–8]. A critical review of
the available literature shows an evident incoherence between
preclinical data and clinical trial design. From in vitro experi-
ments, it seems clear that the administration of pemetrexed
should precede all other drugs, with the possible exception of
irinotecan, to increase cell kill and induce a synergistic effect [9,
10]. Clinical studies of pemetrexed-containing regimens have
ignored this important finding in that the cytotoxics are gener-
ally infused concomitantly. Moreover, pemetrexed is commonly
administered intravenously as a 10-minute infusion, but there
is a strong body of evidence that anti-metabolites such as 5-
fluorouracil and gemcitabine, when given in continuous intra-
venous infusion, show a different efficacy and toxicity pattern
compared with the same dose given as an intravenous bolus
[11–13]. In particular, our preclinical experience suggests that a
prolonged exposure (6 or 12 hours) to pemetrexed leads to
higher antitumor activity than a short exposure (<6 hours) and
that a wash-out time between each drug administration rang-
ing from 48 to 72 hours is essential for the induction of both
cell cycle perturbation and apoptosis [14]. The reasons for this
are not clear, and more in-depth pharmacokinetic studies are
warranted.
The experimental regimen was based on these assump-
tions, in particular the administration of pemetrexed as a
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continuous intravenous infusion followed by a 48-hour wash-
out and then gemcitabine infusion. The chosen dose of peme-
trexed derived from a phase Ib trial performed at our institute,
which showed the feasibility of a 12-hour continuous infusion
of pemetrexed 200 mg/m2 every 2 weeks in patients with
cancer who were previously treated (data not published). How-
ever, clinical results of the present study were not in line with
the preclinical rationale, and the study was closed at the first
step because of important toxicity and the absence of proven
significant activity.
Table 1. Patient characteristics
Characteristic No. of patients, n5 14, n (%)
Median age, years (range) 57 (48–77)
Gender
Male 8 (57.1)
Female 6 (42.9)
PS (ECOG)
0 9 (64.3)
1 4 (28.6)
2 1 (7.1)
Ethnic origin
White 14 (100.0)
Stage IV colorectal cancer 14 (100.0)
Prior chemotherapy for metastatic disease 14 (100.0)
Primary tumor localization
Rectum 3 (21.4)
Colon 11 (78.6)
Site of metastasis
Lung and liver 8 (57.1)
Liver and other sites 3 (21.4)
Liver 2 (14.3)
Lymph nodes and bone 1 (7.2)
Prior radiotherapy
Performed 4 (28.6)
Not performed 10 (71.4)
Prior surgery
Left hemicolectomy 8 (57.1)
Right hemicolectomy 3 (21.4)
Metastases resection 2 (14.3)
Other 1 (28.6)
Abbreviations: PS, performance score; ECOG, eastern cooperative oncology group.
TRIAL INFORMATION
Disease Colorectal cancer
Stage of Disease/Treatment Metastatic/advanced
Prior Therapy More than two prior regimens
Type of Study - 1 Phase II
Type of Study - 2 Single arm
Primary Endpoint Overall response rate
Secondary Endpoint Toxicity
Secondary Endpoint Time to progression
Secondary Endpoint Overall survival
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Additional Details of Endpoints or Study Design
A minimax two-stage Simon design was employed. A 10% response would preclude further study, whereas a 30% response rate
would indicate that further study would be warranted. Using a and b errors of 0.10 and 0.10, respectively, 12 patients were
required in the first stage, and if 1 or 0 responses were observed, the trial had to be terminated. Otherwise, an additional 23
patients were to be enrolled. If 5 or fewer responses were observed in 35 patients, the combination would not have been con-
sidered worthy of further study; however, if 6 or more responses were observed, the combination would have been considered
sufficiently active to warrant further testing.
Investigator’s Analysis Level of activity did not meet planned endpoint
DRUG INFORMATION FOR PHASE II PEMETREXED/GEMCITABINE
Drug 1
Generic/Working name Pemetrexed
Trade name Alimta
Company name Lilly
Drug type
Drug class Antimetabolite
Dose 150 milligrams (mg) per squared meter (m2)
Route Continuous intravenous infusion (cIV)
Schedule of Administration Eight-hour intravenous infusion of pemetrexed 150 mg/m2 on
day 1 and a 30-minute intravenous infusion of gemcitabine
1,000 mg/m2 on day 3 of each cycle, repeated every 14 days
Drug 2
Generic/Working name Gemcitabine
Drug type
Drug class Antimetabolite
Dose 1,000 milligrams (mg) per squared meter (m2)
Route IV
Schedule of Administration Eight-hour intravenous infusion of pemetrexed 150 mg/m2 on
day 1 and a 30-minute intravenous infusion of gemcitabine
1000 mg/m2 on day 3 of each cycle, repeated every 14 days.
PATIENT CHARACTERISTICS FOR PHASE II PEMETREXED/GEMCITABINE
Number of patients, male 8
Number of patients, female 6
Stage Stage IV colorectal cancer
Age Median (range): 57 (48–77)
Number of prior systemic therapies Median (range): 2 in all patients
Performance Status: ECOG 0 — 9
1 — 4
2 — 1
3 — 0
Unknown — 0
Other Not Collected
Cancer Types or Histologic Subtypes
PRIMARY ASSESSMENT METHOD FOR PHASE II PEMETREXED/GEMCITABINE
Number of patients screened 14
Number of patients enrolled 14
Number of patients evaluable for toxicity 14
Number of patients evaluated for efficacy 12
Evaluation method RECIST 1.0
Response assessment CR n5 0
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Metastatic colorectal cancer (mCRC) patients are usually
treated with 5-fluorouracil, oxaliplatin, irinotecan, bevacizumab-
based regimens, and, in selected cases, cetuximab. Regorafenib
and TAS-102 have recently been introduced for the treatment of
refractory disease. There are no further treatment options for fit
patients who are resistant to these drugs. Although gemcitabine
and pemetrexed have shown preclinical and clinical activity in
patients with mCRC, clinical data remain inconclusive [1–8].
Gemcitabine has recognized broad-spectrum activity and is
recommended for treatment in an increasing number of
tumors. However, there is still little clinical proof of its efficacy
in mCRC. A review by Merl et al. evaluating the efficacy and
safety of fluoropyrimidine plus gemcitabine in patients with
mCRC reported objective response rates (ORR) of 30%–38.3%,
median time to progression (TTP) of 4–8.3 months, and median
overall survival (OS) of 9.8–18 months [1].
Pemetrexed is a pyrrolopyrimidine-based antifolate with
proven in vitro activity against folate-requiring enzymes, includ-
ing thymidylate synthase, dihydrofolate reductase, and glycina-
mide ribonucleotide formyltransferase [2]. In vitro studies have
shown that pemetrexed is active against a wide range of
human cell lines, including colon cells and also VRC5 and
HXGC3 human colon xenografts. Phase I clinical trials estab-
lished pemetrexed 600 mg/m2 once every 21 days as a suitable
schedule for phase II trials [3]. Phase II studies of single-agent
pemetrexed in mCRC reported an overall response rate of
about 15% in the first-line setting and no observable responses
in refractory patients [4, 5]. In preclinical models, a synergism
between pemetrexed, oxaliplatin, and irinotecan was observed,
attesting to the potential for using these combination regimens
in clinical trials [6]. Pemetrexed has been studied in combina-
tion with oxaliplatin as first-line in mCRC, showing ORR of
29.6%, TTP of 5.3 months, and OS of 12.3 months [7]. The drug
has also produced interesting ORRs when used in combination
with irinotecan as first- and second-line treatment [8, 9].
A critical review of the available literature shows an evident
incoherence between preclinical data and clinical trial design.
From in vitro experiments, it seems clear that the administra-
tion of pemetrexed should precede all other drugs, with the
possible exception of irinotecan, to increase cell kill and induce
a synergistic effect [10, 11]. Clinical studies of pemetrexed-
containing regimens have ignored this important indication in
that the cytotoxics are generally infused concomitantly. More-
over, pemetrexed is commonly administered intravenously as a
10-minute infusion, but there is a strong body of evidence that
anti-metabolites such as 5-fluorouracil and gemcitabine, when
given in continuous intravenous infusion, show a different effi-
cacy and toxicity pattern compared to the same dose given as
an intravenous bolus [12–14]. In particular, our preclinical expe-
rience suggests that a prolonged exposure (6 or 12 hours) to
pemetrexed leads to higher antitumor activity than a short
exposure (<6 hours) and that a wash-out time between each
Response assessment PR n5 0
Response assessment SD n5 1
Response assessment PD n5 11
Response assessment OTHER n5 0
(Median) duration assessments PFS 2.1 months, CI: 1.7–2.8
(Median) duration assessments OS 5.8 months, CI: 3.9–7.1
ADVERSE EVENTS: PHASE II PEMETREXED/GEMCITABINE
All Dose Levels, Cycle 1
Name NC/NA 1 2 3 4 5 All Grades
Fatigue 14% 7% 29% 50% 0% 0% 86%
Mucositis oral 21% 29% 29% 14% 7% 0% 79%
Anemia 42% 0% 29% 29% 0% 0% 58%
Febrile neutropenia 71% 0% 0% 29% 0% 0% 29%
Platelet count decreased 21% 0% 7% 36% 36% 0% 79%
Neutrophil count decreased 29% 7% 0% 7% 57% 0% 71%
Adverse events among patients undergoing at least one treatment cycle
Abbreviation: NC/NA, no change from baseline/no adverse event.
ASSESSMENT, ANALYSIS, AND DISCUSSION
Completion Study terminated before completion
Terminated reason Toxicity
Pharmacokinetics/Pharmacodynamics Not collected
Investigator’s Assessment Level of activity did not meet planned endpoint
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drug administration ranging from 48 to 72 hours is essential for
the induction of both cell cycle perturbation and apoptosis [15].
The reasons for this are not clear; it can be argued that a longer
exposure of tumor cells to lower doses of the drug may opti-
mize the carrier system much more than higher doses adminis-
tered over a shorter time. More sophisticated pharmacokinetic
studies (intracellular drug concentration) are warranted.
The experimental regimen was based on these assump-
tions, in particular the administration of pemetrexed as a con-
tinuous intravenous infusion followed by a 48-hour wash-out
and then gemcitabine infusion (Fig. 1). The chosen dose of
pemetrexed was derived from a phase Ib trial performed at our
institute that showed the feasibility of a 12-hour continuous
infusion of pemetrexed 200 mg/m2 every 2 weeks in pre-
treated cancer patients (data not published). However, clinical
results were not in line with the preclinical rationale and the
study was closed at the first step because of important toxicity
and the absence of proven significant activity. In particular, no
objective responses or even minor tumor shrinkage (enough to
satisfy partial response (PR) criteria) were seen. The only
patient with stable disease after 8 weeks’ treatment showed
clinical progression immediately after the radiological evalua-
tion. One reason for such a negative result might be the low
activity of gemcitabine and pemetrexed in mCRC. Enrolled
patients had also received several treatments and were pre-
sumed to have chemoresistant disease (Table 1). In addition,
the toxicity profile (Table 2) was not favorable. Grade 4 neutro-
penia and thrombocytopenia were observed in 57.1% and
35.7% of patients, respectively, and 4 (28.7%) patients experi-
enced febrile neutropenia. The most important grade 3–4
nonhematological adverse events were fatigue (50%) and sto-
matitis (21.5%).
Difficulties in translating in vitro results into clinical practice
are inevitable. In our study the duration of pemetrexed contin-
uous infusion and the length of the washout period between
treatments were defined on an empirical basis. This is an
important aspect to consider when conducting translational
research, as it may affect clinical results. Taking into account
the low efficacy and high toxicity associated with the experi-
mental regimen, clinical development is not recommended.
However, further efforts are warranted to verify the efficacy of
alternative schedules of pemetrexed in solid tumors.
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FIGURES AND TABLES
Figure 1. Effect of different schedules of combination of pemetrexed (PEM) with carboplatin (CARBO) (A), gemcitabine (GEM) (B), or mito-
mycin C (MITOC) (C) on three colon cancer cells lines. Cell viability was determined by SRB assay, and the results were expressed as the
mean of an octuplicate from three independent experiments. Bars represent standard deviation (*p< .05). Statistical significance was
determined using the GraphPad Prism Software Holm-Sidak method. Treatment dose: #1 (PEM 1 mM - CARBO 0.8 mM), #2 (PEM 10 mM
- CARBO 8 mM), #3 (PEM 100 mM - CARBO 80 mM), #4 (PEM 1 mM - GEM 0.4 mM), #5 (PEM 10 mM - GEM 4 mM), #6 (PEM 100 mM -
GEM 40 mM), #7 (PEM 1 mM - MITOC 0.03 mM), #8 (PEM 10 mM - MITOC 0.3 mM), and #9 (PEM 100 mM - MITOC 3 mM).
Abbreviations: CARBO, carboplatin; GEM, gemcitabine, MITOC, mitomycin C; SRB, sulforhodamine B; WO, wash-out.
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Table 2. Adverse events among patients undergoing at least one treatment cycle
Adverse Events
No. patients, n5 14, n (%)
Grade 1 Grade 2 Grade 3 Grade 4
Neutropenia 1 (7.1) — 1 (7.1) 8 (57.1)
Febrile neutropenia — — 4 (28.7) —
Leukopenia — — — 1 (7.1)
Thrombocytopenia — 1 (7.1) 5 (35.7) 5 (35.7)
Anemia — 4 (28.7) 4 (28.7) —
Fatigue 1 (7.1) 4 (28.7) 7 (50.0) —
Rash/desquamation 1 (7.1) 1 (7.1) — —
Pruritus — 1 (7.1) — —
Nausea 3 (21.4) 2 (14.4) — —
Anorexia — — 1 (7.1) —
Stomatitis/pharyngitis 4 (28.7) 4 (28.7) 2 (14.4) 1 (7.1)
Diarrhea 1 (7.1) 1 (7.1) — —
Constipation — 1 (7.1) — —
Fever 7 (50.0) — — —
Pain 1 (7.1) 4 (28.7) 1 (7.1) —
Hepatotoxicity — 1 (7.1) 1 (7.1) —
Other 1 (7.1) 8 (57.1) — —
Abbreviation: —, no data.
Click here to access other published clinical trials.
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